Anti-VEGF and anti-EGFR monoclonal antibodies in the first-line therapy for metastatic colorectal cancer - a meta-analysis

Zheng Zhou, William V. Walsh, Venu G. Bathini, Bilal Piperdi

Research output: Contribution to journalArticlepeer-review


Introduction: The optimal Anti-VEGF (vascular endothelial growth factor) and Anti-EGFR (epithelial growth factor receptor) antibody regimen to combine with chemotherapy in the first-line treatment for metastatic colorectal cancer remains to be better defined. Results from randomized controlled trials are variable. Methods: A meta-analysis was performed by searching PubMed, Cochrane Registry, major oncology conferences proceedings until February 2010 for randomized controlled trials of Anti-VEGF and Anti-EGFR in first-line treatment of metastatic colorectal cancer. Summary estimates of progression-free survival, overall survival, overall response rate and 60- day mortality were derived. Effect of k-ras status was stratified in trials involving Anti-EGFR. Results: Nine trials were included, including three anti-VEGF +/- chemotherapy, n=2422; four anti-EGFR +/- chemotherapy, n=4348 and two anti-VEGF with chemotherapy +/- anti-EGFR, n=1601. Adding anti-VEGF to chemotherapy showed a 20-30% risk reduction in disease progression and mortality, and a higher response rate. Benefit of anti-EGFR was seen only in κ-ras wild type patients with 20% reduction in disease progression and 10% reduction of mortality. Adding both antibodies to chemotherapy showed worse survival outcomes. Conclusion: Benefit of adding anti-VEGF in first-line metastatic colorectal cancer treatment is well pronounced. Combining anti-EGFR with chemotherapy showed significant increase in response rate and PFS in κ-ras wild type patients. Adding both antibodies to chemotherapy appeared inferior regardless of κ-ras status.

Original languageEnglish (US)
Pages (from-to)282-289
Number of pages8
JournalCurrent Cancer Therapy Reviews
Issue number4
StatePublished - Nov 2011
Externally publishedYes


  • Anti-EGFR
  • Anti-VEGF
  • Meta-analysis
  • Metastatic colorectal cancer
  • Monoclonal antibody

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Cancer Research


Dive into the research topics of 'Anti-VEGF and anti-EGFR monoclonal antibodies in the first-line therapy for metastatic colorectal cancer - a meta-analysis'. Together they form a unique fingerprint.

Cite this